Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells

Rachel Elizabeth Cooke1,2*, Kylie Margaret Quinn3, Hang Quach2,4, Simon Harrison2,4, Henry Miles Prince2,4, Rachel Koldej1,2 and David Ritchie1,2,4

1 Australian Cancer Research Foundation Translational Research Laboratory, Royal Melbourne Hospital, Melbourne, VIC, Australia, 2 Department of Medicine, University of Melbourne, Melbourne, VIC, Australia, 3 School of Health and Biomedical Sciences, RMIT University, Melbourne, VIC, Australia, 4 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

INTRODUCTION

Multiple myeloma (MM) is a malignancy of plasma cells within the bone marrow (BM) (1, 2) that is typically diagnosed in patients over the age of 60 years old (3). Treatment for MM has evolved over the last 10 years with the introduction of immune modulatory drugs (IMiDs) and proteasome inhibitors. This has led to a significant increase in life expectancy (2, 4), which is most pronounced in patients under 60 years old (5). However, it is notable that the typical age of onset...
for MM coincides with marked decline in immune function during normal biological aging driven by thymic involution and immunosenescence.

From 60 years old, both the number and repertoire diversity of T_N cells declines substantially due to a process known as thymic involution (6, 7). Thymic involution refers to a loss of thymic stromal tissue and function, which limits de novo production of naïve T (T_N) cells. With this decline in de novo T_N cell production, homeostatic proliferation of peripheral T cells appears to compensate and increases with age (8). As a result, in the event of a sudden decline in the number of lymphocytes (such as might occur during high dose chemotherapy), the aged thymus has limited capacity for T_N cell output (9, 10). Instead, repopulation of the peripheral T cell population is predominantly driven by lymphopenia-induced proliferation, mediated by the increased availability of γc cytokines, such as IL-7 and IL-15. Lymphopenia-induced proliferation favors expansion of CD8+ memory T cells, because CD8+ memory T cells express higher levels of a component of the IL-15 receptor (CD122) (11) and CD4+ T cell homeostatic expansion is limited by IL-7-dependent STAT-1 activation (12). More recently, signaling from γc cytokines has been seen to drive metabolic remodeling in T cells in mouse models of aging, inflammation, and lymphopenia (13–15), but the impact of lymphopenia-induced therapies on T cell metabolism in aged humans has not been defined.

Immunosenescence refers to a loss of intrinsic function in immune cells, which can undermine responses to vaccines, infections, and cancer (16). Chronic age-related inflammation and metabolic stress are thought to be significant drivers of immunosenescence for a variety of immune cells, including CD4+ and CD8+ T cells (17, 18). During MM disease, it is well established that MM cells can create a microenvironment of chronic inflammation in the BM, characterized by increased production of IL-6 in particular (19). IL-6 sustains tumor survival, but it also drives production of senescent cells that exhibit a senescence-associated secretory phenotype (20, 21), all of which are predicted to augment dysfunction in CD4+ and CD8+ T cells. Inflammation-associated cytokine stimulation is also known to drive metabolic changes in a variety of immune cells, including T cells (13–15). Given the complex relationship between T cell homeostasis, inflammation, and aging, understanding the shifts in the immune system that result from normal aging, MM disease and MM therapies will be critical for implementing immune therapies in MM patients (22).

Previously, we demonstrated a loss of T_N cells in the peripheral blood (PB) of MM patients, with a reciprocal expansion of effector memory (T_EM) cells (23). In the CD8+ T cell population, a loss of T_N cells is already observed at diagnosis and is equivalent to the loss of T_N cells seen in elderly healthy donors (HD). In contrast, in the CD4+ T cell population, T_N cells are relatively preserved in the elderly and newly diagnosed MM (NDMM), with significant loss of T_N cells only observed in relapsed/refractory MM (RRMM) (24). This also leads to a decrease in CD4:8 ratio, which is a characteristic finding in MM with disease progression (23, 25). While prior studies of patients with NDMM and RRMM concluded that changes in NK and T cell populations were corticosteroid-induced and/or disease-driven (23, 24, 26–28), autologous stem cell transplant (ASCT) and T cell-depleting therapies form the backbone of treatment for medically fit MM patients, and their long-term impact on T cell function has not been well-described.

In this study, we demonstrate that ASCT and/or MM disease does irreversibly change the composition of T cell populations, with a dramatic loss of CD4+ T_N cells and reciprocal increase in CD8+ effector memory T cells, and an increase in PD1-expressing CD4+ T cells. We also observe metabolic changes in T cells from RRMM patients, with increased expression of transcripts for mitochondrial respiration, increased mitochondrial load, and decreased reactive oxygen species (ROS), which suggests a loss of metabolic fitness. We propose a model where ASCT and/or MM disease-derived inflammation drives increased inflammatory and γc cytokine signaling and lymphopenia-induced proliferation and accelerated immunosenescence, which would mediate the dramatic loss of T_N cells in MM patients and metabolic remodeling in the remaining T cells. These findings inform our current treatment protocols for MM and will guide integration of new immune-based therapies for MM. While lymphopenia may drive CD4+ T_N cell loss, we may be able to intervene with dendritic cell (DC) vaccination, checkpoint blockade, or metabolic interventions during post-ASCT lymphopenia to better support the recovering T cell population. Furthermore, the collection of T cells prior to ASCT (as opposed to at the time of relapse) would likely provide a more efficacious chimeric antigen receptor (CAR)-T product.

MATERIALS AND METHODS

Human Samples and Cells

All research was conducted in full compliance with principles of the “Declaration of Helsinki,” Good Clinical Practice, and within the laws and regulations of Australia. Cryopreserved peripheral blood mononuclear cells (PBMCs) were analyzed from MM patients enrolled on two historical clinical trials: LITVACC (ACTRN1261300344796) that recruited NDMM patients and REVLYTE (NCT00482261) that recruited RRMM patients, which are illustrated in Figure 1A.

Newly diagnosed MM patients received four induction cycles of lenalidomide and dexamethasone (LEN/DEX) followed by ASCT, and they were then partitioned into one of two study arms, with either (i) monthly DC vaccines + LEN or (ii) LEN ± DEX maintenance therapy. Both study arms have been combined in this analysis as sample numbers were underpowered to detect any small variances. Paired patient PBMC samples (where available) were analyzed at three consecutive time points: cycle 4 of induction (Pre-ASCT, n = 29), at maintenance cycle 4 after ASCT (Post-ASCT, n = 21), and at last follow-up [end of treatment (EOT), n = 21]. The mean time to last follow-up was well over 2 years at 1069 days (range: 397–1780 days), to ensure maximal peripheral leukocyte reconstitution.

Relapsed/refractory MM patients were also treated with successive cycles of LEN/DEX and evaluated for stable disease, and for those who had stable disease, we analyzed PBMC samples
CD4:8 is reduced post-ASCT and in RRMM. (A) Time points analyzed by flow cytometry (described in section “Materials and Methods”). In newly diagnosed MM (NDMM), paired samples (where available) were analyzed prior to autologous stem cell transplant (pre-ASCT, n = 29), post-ASCT (n = 21) and at end of treatment (EOT, n = 21). In relapsed/refractory MM (RRMM), samples were analyzed after six cycles LEN/DEX and subdivided into those patients who had not had a prior ASCT (n = 5) and those with prior ASCT (n = 7). (B) The proportion of CD3+ T cells that are CD4+ (black circle) or CD8+ (clear circle) at serial time points in NDMM (top) and in RRMM (bottom) compared with HD. Baseline samples (NDMM n = 21, RRMM n = 10) analyzed in a prior study (23) are incorporated for interest. (C) CD4:8 ratio in NDMM (top) and in RRMM (bottom) compared with HD. Baseline samples (NDMM n = 21, RRMM n = 10) analyzed in a prior study (23) are incorporated for interest but are not included in statistical analysis. Statistical significance was determined using the Mann–Whitney test (*p < 0.05, **p < 0.001).

Peripheral blood mononuclear cells from age-matched HD were used as a control group and were collected via the Australian Red Cross Blood Service and the Victorian Blood Donor Registry.

**T Cell Flow Cytometric Analysis**

Flow cytometry was performed using Fixable viability stain 700 (BD Horizon) and directly conjugated anti-human antibodies: CD3 (SK7, BD Biosciences), CD4 (RPA-T4, BD Pharmingen or SK3, BD Horizon), CD8 (RPA-T8, BD Pharmingen), CD45RA (H100, eBiosciences), CD197 (CCR7) (3D12, eBiosciences) and CD279 (PD1) (EH12, BD Horizon). Cell surface staining was performed with 5 × 10^6 to 1 × 10^7 PBMCs in a 100-µl cell suspension of FACS buffer and antibody master mix for 30 min at 4°C. Cells were washed and resuspended in FACS buffer or complete RPMI containing mitochondrial fluorescent dyes for mitochondrial assessment. Lymphocytes were gated using forward and side scatter, followed by doublet and dead cell removal. BD Anti-Mouse or Anti-Goat Comp Beads were used to optimize fluorescence compensation settings for analysis. Fluorescence minus one (FMO) controls were used to assist with gating. Analysis was performed on a BD LSR Fortessa and analyzed using FlowJo software (Version 10). T cell differentiation subsets were defined as the following: Naive (TN); CD3+CD4+/8+CD45RA+CCR7+, central memory (T<sub>CM</sub>); CD3+CD4+/8+CD45RA−CCR7+, effector memory (T<sub>EM</sub>); CD3+CD4+/8+CD45RA−CCR7−, and effector memory CD45RA+ (T<sub>EMRA</sub>); CD3+CD4+/8+CD45RA+CCR7−.

**RNA Sequencing**

CD4+ T cells were enriched from PBMCs using the MACS<sup>®</sup> human CD4+ T cell isolation kit, as per the manufacturer's instructions. CD4+ T cell purity was >80%. RNA was extracted with Trizol, and cDNA library creation and RNA sequencing were performed by the Australian Genome Research Facility at the Walter and Eliza Hall Institute. Because there was significant RNA degradation in the sample set, the SMART<sub>er</sub> Stranded Total RNA-Seq Kit<sup>®</sup> (Takara Bio USA) protocol was used, which incorporates a ribosomal RNA depletion. Genes needed to pass a 20 read threshold in >80% of samples in order to be analyzed. Bioinformatic analysis was performed at Melbourne Bioinformatics, University of Melbourne, utilizing the Limma linear model (29).

**Real-Time qPCR**

CD4<sup>+</sup> and CD8<sup>+</sup> T cells were enriched from PBMCs using the MACS<sup>®</sup> human CD4+ T cell isolation kit or MACS<sup>®</sup> human CD8<sup>+</sup> Microbeads (Miltenyi Biotec), as per the manufacturer’s instructions. RNA was extracted with Trizol and cDNA was synthesized using the Superscript VILO cDNA kit (Thermo
Fisher Scientific), as per the manufacturer’s instructions. Target genes were analyzed using TaqMan gene expression assays with TaqMan Fast Universal master mix on the QuantStudio 7 Flex Real-Time PCR system (Thermo Fisher Scientific), as per the manufacturer’s instructions. The housekeeping gene TBP was used as the endogenous control to calculate relative gene expression.

**Mitochondrial Staining**

After cell surface staining, cells were incubated at 37°C for 30 min in complete RPMI containing mitochondrial fluorescent dyes (Thermo Fisher Scientific), using a combination of MitoTracker deep red FM (MTdr) at 1:20,000 and either CellRox® Orange reagent (CellRoxO) at 1:1000 or tetramethylrhodamine, methyl ester (TMRM) at 1:3000. Cell suspensions were washed and resuspended in T cell media for flow cytometric analysis.

**Statistical Analysis**

Data were analyzed using GraphPad Prism software (version 7).

**RESULTS**

**Phenotypic Changes in the Composition of T Cell Subsets**

To track changes in T cell populations throughout the course of MM disease and treatment, we analyzed PBMCs from patients with NDMM and RRMM collected at serial time points throughout their treatment and compared with age-matched HD. Study design and analysis time points are described in section “Materials and Methods” and in Figure 1A, and patient characteristics are shown in Supplementary Tables 1, 2. Unfortunately, baseline samples from patients prior to any treatment were not available for this analysis, but they have been described in previous work (23), which we include for interest but do not include in statistical analysis as these are not matched samples and it should be noted that different fluorochromes and gating strategies were used in the prior analysis.

In NDMM, the CD4:8 ratio was similar to HD in patients at baseline and pre-ASCT after four induction cycles of LEN/DEX, but it was significantly reduced post-ASCT and did not recover to baseline by EOT (Figures 1B,C, left). Prolonged CD4+ T cell depletion has been described after ASCT in children and young adults (10), but the CD4:8 ratio recovers to baseline levels by 1 year post-ASCT (30). Our results in an older population differ in this regard, and support findings by Chung et al. (30), who also demonstrated a reduction in the CD4:8 ratio in MM patients after ASCT up to 1 year post-ASCT. Subanalysis of the population that received DC vaccines (n = 8) suggested a trend toward expansion of the CD8+ T cell population (and further reduction of CD4:8) compared with those receiving LEN/DEX therapy (n = 13) at the post-ASCT time point; however, this did not reach statistical significance and was indistinguishable by EOT (Supplementary Figure 1).

In RRMM (at baseline and after LEN/DEX treatment, irrespective of prior ASCT), the CD4:8 ratio was also significantly reduced compared with HD (Figures 1B,C, right), although we note that the mean CD4:8 ratio in the this HD group is higher than that used for the NDMM comparison that may reflect heterogeneity in the normal population and/or minor differences in the fluorochromes used. The CD4:8 ratio is likely reduced in RRMM patients as a whole as they were probably treated previously with cyclophosphamide (commonly used in induction regimens in Australia), which is known to induce lymphopenia.

We next observed the differentiation status of CD4+ and CD8+ T cell populations over the course of treatment. In NDMM pre-ACST, phenotypic composition was similar to HD, but post-ASCT, there was a significant decrease in the proportion of CD4+ T cells that were T_N and T_CM cells and a reciprocal increase in T_EM cells, which persisted to EOT (Figures 2A,B, left). In RRMM (at baseline and with treatment), there was also a significant decrease in the proportion of CD4+ T_N cells but, unlike in NDMM, both the CD4+ T_CM and T_EM populations had reciprocally expanded (Figure 2C, left). These shifts in phenotypic composition were not evident in CD8+ T cells, because T_EMRA cells are already an established subset in older HD (Figures 2B,C, right).

**There Are Temporal and Compartmental Differences in PD-1 Expression Between CD4+ and CD8+ T Cells**

In the Vk’MYC murine model of MM, PD1 expression was shown to transiently increase on T cells 30 days post-transplant (31). PD-L1 blockade also increased the efficacy of hematopoietic stem cell transplant, adoptive T cell transfer, and a post-transplant DC vaccine (31), and increased survival when administered during the homeostatic proliferation phase after non-myeloablative total body irradiation (32). This suggests that PD1/PD-L1 monoclonal antibodies may be beneficial post-ASCT, but human studies have not demonstrated significantly altered PD1 expression post-ASCT (30). We wanted to further dissect PD1 expression in CD4+ and CD8+ T cell subsets during MM treatment.

In CD4+ T cells, the proportion expressing PD1 was increased in both NDMM and RRMM patients compared with HD and was highest post-ASCT in NDMM (Figures 3B,C, left). In CD8+ T cells, there was no statistically significant change but there did appear to be two populations post-ASCT: one with and one without PD1 expression (Figures 3B,C, right). Subanalysis shows a trend toward increased % PD1+ in the group receiving DC vaccine but this does not reach statistical significance (Supplementary Figure 3). PD1+ expression remained high in CD4+ T cells at EOT, while it returned to normal in CD8+ T cells (Figure 3B). The latter finding was also described in the post-allogeneic stem cell transplant setting, where PD1 facilitated apoptosis of alloreactive CD8+ T cells by increasing ROS (33).

PD1+ events were then backgated to define the phenotypic distribution of PD1 expression (Supplementary Figure 2).
In HD, most PD1+ cells were TEM phenotype, with minor proportions of TN, TCM, and TEMRA phenotypes; however, there were significant proportions of TCM and TEMRA in CD4+ and CD8+ PD1+ populations, respectively. We then assessed PD1 expression in T cell differentiation subsets (Figure 3D). In CD4+ T cells, the proportion of TN, TCM, and TEMRA that were PD1+ increased significantly in NDMM post-ASCT and in RRMM with prior ASCT, compared with HD (Figures 3E,F, left). The proportion of CD4+ TCM that were PD1+ also remained elevated at EOT in NDMM. In CD8 T cell subsets, differences in PD1
Fatty Acid \(\beta\)-Oxidation Is Increased in T Cells From RRMM Compared With HD

T cell function and survival are supported by the selective use of distinct metabolic pathways (34–36). For example, effector T cell activation and proliferation is supported by a shift toward aerobic glycolysis, while memory T cells utilize fatty acid oxidation (FAO) to fuel mitochondrial respiration. Furthermore, as previously mentioned, animal models demonstrate that aging, inflammation, and lymphopenia can all alter the metabolic capacity of T cells to promote mitochondrial respiration (13–15).

We performed preliminary RNA-Seq analysis on CD4\(^{+}\) T cells from HD \((n = 2)\) and RRMM \((n = 2)\) samples to identify differentially expressed genes (DEGs). When lists of DEGs were interrogated for significant enrichment of specific biological pathways in the KEGG databases, the top upregulated pathways included RAP1, PI3K-AKT, cAMP, calcium, and PPAR signaling pathways (Supplementary Figure 4), which can augment specific metabolic responses, particularly in relation to FAO and mitochondrial respiration.

To further explore this, we evaluated the expression of key genes for glycolysis and FAO (Table 1) in CD4\(^{+}\) and CD8\(^{+}\) T cells with a larger cohort of RRMM and HD samples by using quantitative PCR; sample characteristics are described in Supplementary Table 3. There was no difference in relative RNA quantitation (RQ) between RRMM and HD for nearly all of the glycolysis genes analyzed; the one exception was PKM (pyruvate kinase), which was increased in RRMM compared with HD (Figure 4A). While pyruvate kinase is in the glycolytic pathway, it generates pyruvate that can either undergo aerobic glycolysis or be converted into acetyl CoA to provide substrate for mitochondrial respiration. In contrast, the expression of nearly all of the FAO genes were significantly higher in both CD4\(^{+}\) and CD8\(^{+}\) T cells in RRMM compared to HD (Figure 4B). These results suggest that FAO and mitochondrial respiration is upregulated in T cells in RRMM compared with HD.

Mitochondrial Mass Is Significantly Increased in T Cell in RRMM

Given that genes associated with FAO and mitochondrial respiration were upregulated in T cells in RRMM, we then assessed mitochondrial mass using the MitoTracker\textsuperscript{TM} Deep Red FM dye (MTdr). MTdr staining was significantly increased in
TABLE 1 | Genes analyzed by qPCR to assess glycolysis and fatty acid β-oxidation in T cells.

<table>
<thead>
<tr>
<th>Mode of metabolism</th>
<th>Gene</th>
<th>Abbreviation</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycolysis</td>
<td>Hexokinase 1</td>
<td>HK1</td>
<td>Hexokinases phosphorylate glucose to produce glucose-6-phosphate, the first step of glycolysis. This gene encodes a ubiquitous form that localizes to the outer membrane of mitochondria.</td>
</tr>
<tr>
<td></td>
<td>Pyruvate kinase, muscle</td>
<td>PKM</td>
<td>Enzyme involved in the production of pyruvate that can either undergo aerobic glycolysis or be converted to acetyl CoA (a substrate of the TCA cycle)</td>
</tr>
<tr>
<td></td>
<td>Lactate dehydrogenase, A and B subunits</td>
<td>LDHA, LDHB</td>
<td>Catalyze the interconversion of pyruvate and lactate in the last step of aerobic glycolysis</td>
</tr>
<tr>
<td>Fatty acid β-oxidation</td>
<td>Carnitine palmitoyl transferase 1A</td>
<td>CPT1A</td>
<td>Rate-limiting enzyme in the transport of fatty acids across the mitochondrial inner membrane</td>
</tr>
<tr>
<td></td>
<td>Acyl-CoA dehydrogenase, very long chain</td>
<td>ACADVL</td>
<td>Catalyzes the first step of the mitochondrial fatty acid β-oxidation pathway</td>
</tr>
<tr>
<td></td>
<td>Acetyl-CoA acyltransferase 2</td>
<td>ACAA2</td>
<td>Catalyzes the last step of the mitochondrial fatty acid β-oxidation pathway</td>
</tr>
</tbody>
</table>

FIGURE 4 | Expression of metabolic genes in CD4+ and CD8+ T cells. Relative transcript expression assessed by qPCR for (A) glycolysis-associated genes and (B) FAO-associated genes. Study groups: Healthy donor (HD) (n = 12), RRMM No ASCT (n = 5), RRMM ASCT (n = 9). Statistical significance was determined using the Mann–Whitney test (*p < 0.05, **p < 0.01, ***p < 0.001). 1Insufficient RNA extracted from one CD8+ sample for analysis. 2Insufficient RNA extracted from four CD4+ samples for analysis.

Mitochondrial ROS Levels Are Reduced in T Cells in RRMM

CD4+ and CD8+ T cells in RRMM had elevated mitochondrial mass, but these mitochondria may not necessarily be functional. To assess the functionality of mitochondria, we then measured ROS, which are produced during normal mitochondrial respiration, using the CellROX Orange dye. We gated on cells with high mitochondrial mass for internal consistency (Figure 6A) and saw that both CD4+ and CD8+ T cells from RRMM patients showed significantly lower ROS levels than HD (Figure 6B). This reduction in ROS levels was evident across all T cell populations (Figure 6C). In HD, ROS levels were highest in TCM and TEM cells, which would be expected as these cells rely more heavily on mitochondrial respiration to meet their energy demands, but in RRMM, this difference was reduced (Figure 6D).

Mitochondrial Membrane Potential (Δψm) Is Increased in CD4+ TCM Cells in RRMM

High mitochondrial mass accompanied by low ROS levels is suggestive of reduced mitochondrial activity. To assess whether mitochondria were still functional, we assessed mitochondrial membrane potential (Δψm) using the tetramethylrhodamine, methyl ester dye (TMRM), which is retained in mitochondria with intact membrane potential. We again gated on cells with high mitochondrial mass for internal consistency and saw that Δψm was significantly higher in the CD4+ T cells from RRMM.
Evidence of the detrimental effect of ASCT. Induces molecular aging of T cells (37), providing further \( p16^{INK4a} \) whether in the form of vaccination or infection. Analysis of affect an individual's ability to respond to new or recall antigens, T cells to reconstitute the T cell pool will likely significantly heavy reliance on homeostatic proliferation of oligoclonal CD8 T cells (23), which would be consistent with our observation of a predominance of CD8 T EM and T EMRA cells. The paucity of new thymic emigrants and a skewing of the T cell population toward a predominance of CD8 T EMRA cells due to superior cytokine production of CD4 T cells and cytotoxicity of CD8 T cells (41). Furthermore, the potency of CAR-T cell therapy is dramatically enhanced by generating CD8 T cells derived from T N and T CM cells were shown to be more efficacious than those from than T EM cells due to superior cytokine production of CD4 T cells and cytotoxicity of CD8 T cells (41). Therefore, a CAR-T product generated from T cells from a heavily pre-treated, immunosenescent individual would be expected to be impaired. A practical approach in the clinic to maximize the effectiveness of a CAR-T cell product in MM patients could be to collect and store T cells prior to ASCT, before the shift in composition of the T cell population, when a higher number of naïve and stem cell memory T cells might be collected. patients compared to HD, but there was no significant difference for CD8 T cells (Figure 7A). The RRMM population appeared to be bimodal and, to compare the phenotypic composition of these two subpopulations, we back-gated TMRM− and TMRM+ events (Figure 7B, left). A high proportion of TMRM+ T cells were T CM phenotype, particularly within the CD4 T cell population (Figure 7B, right), suggesting that T CM cells are the most metabolically active subset.

**DISCUSSION**

Autologous stem cell transplant remains a backbone of MM treatment in medically fit patients, but our findings suggest that ASCT and lymphopenia-inducing therapies in MM have a largely irrecoverable effect on the CD4 T cell population. We illustrate that these therapies contribute toward a reduction in the CD4:8 ratio (Figure 1) and CD4+ T N cells (Figure 2), with a skewing of the T cell population toward a predominance of CD8 T EM and T EMRA cells, thereby accelerating changes seen with immunosenescence. Prior analysis of these trial populations [although other studies have pointed to similarities in T cell populations from the PB and BM (23, 38)], the superiority of newer technologies such as mass spectrometry to better identify canonical populations, and the low numbers of samples in the RRMM group.

Nevertheless, our findings are particularly relevant for the utility and production of autologous CAR-T cells in MM. It appears that CAR-T cell production is best achieved with relatively undifferentiated T cells, such as T N and stem cell memory subsets (39, 40). In mouse models of lymphoma, CAR-T cells derived from T N and T CM cells were shown to be more efficacious than those from than T EM cells due to superior cytokine production of CD4 T cells and cytotoxicity of CD8 T cells (41). Furthermore, the potency of CAR-T cell therapy is dramatically enhanced by generating CD8 T cells from T CM cultured with CD4+ T cells. In humans, Garfall et al. (42) found that a higher frequency of CD8+CD45RO−CD27+ T cells and a higher CD4:8 ratio at the time of leukapheresis for CAR-T production were the key factors associated with superior clinical outcome. Therefore, a CAR-T product generated from T cells from a heavily pre-treated, immunosenescent individual would be expected to be impaired. A practical approach in the clinic to maximize the effectiveness of a CAR-T cell product in MM patients could be to collect and store T cells prior to ASCT, before the shift in composition of the T cell population, when a higher number of naïve and stem cell memory T cells might be collected.

We acknowledge some limitations in our analysis including the restriction of T cell analysis to the PB compartment and a higher CD4:8 ratio at the time of leukapheresis for CAR-T production were the key factors associated with superior clinical outcome. Therefore, a CAR-T product generated from T cells from a heavily pre-treated, immunosenescent individual would be expected to be impaired. A practical approach in the clinic to maximize the effectiveness of a CAR-T cell product in MM patients could be to collect and store T cells prior to ASCT, before the shift in composition of the T cell population, when a higher number of naïve and stem cell memory T cells might be collected.

It was, however, interesting to note that our findings of an increase in the proportion of CD4+ T cells with a T CM phenotype in LEN/DEX-treated RRMM (Figure 2C) were also mirrored in the QUIREDEX trial (LEN ± DEX in high-risk smoldering MM).
Cooke et al. T Cell Metabolic Dysfunction in MM

FIGURE 6 | Reactive oxygen species (ROS) levels in RRMM. (A) Gating strategy for assessment of ROS in CD4+ and CD8+ T cells with high mitochondrial mass (MTdr hi cells), using geometric mean fluorescence intensity (MFI) of CellRox Orange (CellRoxO). (B) Box and whisker plots of CellRoxO MFI in CD4+ and CD8+ T cells from RRMM and HD. (C) Box and whisker plots of CellRoxO MFI in CD4+ and CD8+ T cell subsets from RRMM and HD. (D) Comparison of CellRoxO MFI in T cell differentiation subsets across RRMM (pooled) and HD. Study groups as described in Figure 1. Statistical significance in all figures was determined using multiple Student's t-tests with the Holm–Sidak method applied (*\( p < 0.05 \), **\( p < 0.01 \), ***\( p < 0.001 \)).

(43). This trial reported a significant increase in the proportion of CD4+ T\(_{\text{CM}}\) cells by cycle 9 of treatment and, moreover, CD4+ T cells were both functional in terms of cytokine production and proliferative as assessed by expression of activation and proliferation markers. It is not clear, however, whether this change is indicative of re-engagement of the immune system in disease control and/or is related to lenalidomide treatment, and we await the long-term outcome of this trial.

We also show that the frequency of PD1+CD4+ T cells increases post-ASCT and in RRMM, particularly within the CD4+ T\(_{\text{CM}}\) cell subset (Figure 3), which would be expected to impede tumor surveillance and DC vaccination. In previous work, we demonstrated that the frequency of T\(_{\text{REGS}}\) increases post-ASCT (Supplementary Figure 5) and with LEN/DEX in RRMM (44), which could upregulate PD-L1 expression on DCs. However, increased PD-1 expression can also indicate proliferation, as PD-1 is upregulated on initial T cell activation and its expression increases with sustained TCR signaling (45) or chronic antigen stimulation due to infection or tumor. To explore this possibility, further analysis of epitope specificity, TCR repertoire, and telomere length would be of interest. It is possible that a large proportion of these cells are CMV-specific, as oligoclonal expansions can develop in older humans (46), but it is also plausible that this population contains MM-specific T cell clones, the presence of which have been associated with long-term survival (47, 48).

Transcriptional and metabolic analyses of CD4+ and CD8+ T cells in RRMM showed significant increases in FAO transcripts
FIGURE 7 | Mitochondrial membrane potential (Δψm) in T cell populations in RRMM. Mitochondrial membrane potential was measured in T cell subsets by geometric mean fluorescence intensity (MFI) of TMRM. (A) TMRM MFI in CD4+ and CD8+ T cells from healthy donors and RRMM: (left) Gating strategy and (right) scatter plots. (B) CD4+ and CD8+ T cells with high mitochondrial mass (MTdr staining) from RRMM were further subdivided into TMRM− and TMRM+ events (gating strategy to the left) and backgated into T cell differentiation subsets, as shown in stacked bar charts of the mean frequency (right). Study groups as described in Figure 1. Statistical significance was determined using multiple Student’s t-tests with the Holm–Sidak method applied (*p < 0.05, **p < 0.01, ***p < 0.001).

Memory T cells are known to have higher mitochondrial mass and engage FAO for their energy requirements, while T_N cells have low mitochondrial mass and low energy requirements (34). Accordingly, the shift in cell proportions after ACST, with a loss of T_N cells and an increase in T_CM/EM cells, is likely to account for some of the increase in FAO transcripts and mitochondrial mass. However, it should be noted that an increase in mitochondrial mass was observed at all T cell differentiation states. This global increase could be driven by lymphopenia-associated IL-15 signaling, as IL-15 is known to promote CPT1a expression and FAO engagement and promote mitochondrial biogenesis (49, 50). Mitochondrial mass was highest in T_CM cells and, notably, T_N cells. This suggests that the remaining T_N cells are not truly naïve and they may have acquired some memory-associated metabolic characteristics during ASCT, likely from lymphopenia-associated signals.

Given the increased mitochondrial mass in T cells in RRMM, the reduction in ROS levels was unexpected (Figure 6). A potential explanation for discordance between mitochondrial mass and ROS production is that the mitochondria that accumulate in RRMM T cells may be less metabolically fit. This is consistent with the relatively low Δψm that was observed in CD8+ T cells with RRMM (Figure 7A). This effect may again be driven by lymphopenia-induced IL-15 signaling, as it was recently shown that effector CD8+ T cells transferred into irradiated mice had increased mitochondrial content but lower Δψm compared with those transferred into IL-15-deficient irradiated mice (13). In contrast, RRMM CD4+ T cells exhibited elevated Δψm compared with HD but high Δψm associated with the T_CM subset (Figure 7B), highlighting that CD4+ T_CM remain a metabolically active subset. Clarification of the metabolic fitness of these cell subsets with further metabolic studies would be beneficial. Unfortunately, this was not feasible in this analysis.
due to the effects on mitochondria by lengthy cryopreservation of these samples and limited duplicate samples but would be important in future prospective studies.

**CONCLUSION**

Taken together, our findings show that the composition and metabolic profile of the T cell compartment shifts significantly over time in MM. This is likely a consequence of an interplay between aging, duration of disease, and cumulative treatment, but ASCT clearly has a dominant role. Given the inherent variability in these processes, the use of phenotypic and metabolic biomarkers to immunologically profile a patient at the time of clinical decision making will aid in directing and optimizing therapy for MM. Furthermore, if metabolic remodeling can be attenuated without reducing reconstitution after ASCT, it may better preserve functionality in T cell populations.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation. The RNAseq data is accessible under accession number PRJNA658707 at https://www.ncbi.nlm.nih.gov/bioproject/PRJNA658707/.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Peter MacCallum Cancer Centre. The patients/participants provided their written informed consent to participate in this study.

**REFERENCES**


**AUTHOR CONTRIBUTIONS**

RC designed and performed the laboratory research, analyzed the data, and wrote the manuscript. KQ made significant assistance with writing. SH, HQ, HP, and DR were principal investigators for the Litvacc and/or RevLite clinical trials. RK and DR assisted with the research design and editing of the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This research was funded by the Leukaemia Foundation Australia and supported by the University of Melbourne, the Royal Melbourne Hospital, and the Peter MacCallum Cancer Centre. Bioinformatic analysis of the RNA-Seq data was provided by Jessica Chung at Melbourne Bioinformatics (University of Melbourne).

**ACKNOWLEDGMENTS**

We acknowledge the assistance of Dr. Sarah Gabriel and Prof. Axel Kallies at the Peter Doherty Institute for Infection and Immunity with the mitochondrial staining experiments. cDNA library preparation and RNA sequencing were performed by the Australian Genome Research Facility (Victorian Comprehensive Cancer Centre, Melbourne).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2020.02153/full#supplementary-material


29. Bryant C, Suen H, Brown R, Yang S, Favaloro J, Aklilu E, et al. Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable...
Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Cooke, Quinn, Quach, Harrison, Prince, Koldej and Ritchie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Author/s: Cooke, RE; Quinn, KM; Quach, H; Harrison, S; Prince, HM; Koldej, R; Ritchie, D

Title: Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells

Date: 2020-09-03


Persistent Link: http://hdl.handle.net/11343/252572

License: CC BY